Global Chemokine Expression in Systemic Sclerosis (SSc): CCL19 Expression Correlates with Vascular Inflammation in SSc Skin

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2013 Jul 23

PMID 23873879

Citations 30

Authors

Allison L Mathes

Romy B Christmann

Giuseppina Stifano

Alsya J Affandi

Timothy R D J Radstake

G Alessandra Farina

Cristina Padilla

Sarah McLaughlin

Robert Lafyatis

Affiliations

Soon will be listed here.

Abstract

Objective: To characterise global chemokine expression in systemic sclerosis (SSc) skin in order to better understand the relationship between chemokine expression and vascular inflammation in this disease.

Methods: We investigated chemokine mRNA expression in the skin through quantitative PCR analysis comparing patients with diffuse cutaneous (dcSSc) or limited cutaneous (lcSSc) disease with healthy controls. We tested correlations between the most regulated chemokines and vascular inflammation and macrophage recruitment. CCL19 expression was examined in human primary immune cells treated with innate immune activators.

Results: The chemokines, CCL18, CCL19 and CXCL13, were upregulated in dcSSc skin, and CCL18 in lcSSc skin. Expression of CCL19 in dcSSc skin correlated with markers of vascular inflammation and macrophage recruitment. Immunofluorescence data showed CCL19 colocalisation with CD163 macrophages in dcSSc skin. In vitro studies on human primary cells demonstrated that CCL19 expression was induced after toll-like receptor activation of peripheral blood mononuclear cells and separated populations of CD14 monocytes.

Conclusions: CCL18, CCL19 and CXCL13-chemoattractants for macrophage and T cell recruitment-were three of six chemokines with the highest expression in dcSSc skin. Increased CCL19 expression in the skin suggests a role for CCL19 in the recruitment of immune cells to the peripheral tissue. Induction of CCL19 in macrophages but not structural cells indicates a role for skin-resident or recruited immune cells in perivascular inflammation. This study demonstrates that CCL19 is a sensitive marker for the perivascular inflammation and immune cell recruitment seen in dcSSc skin disease.

Citing Articles

RAPO Attenuates Dermal and Pulmonary Fibrosis in a Mouse Model of Systemic Sclerosis through Macrophage Modulation and Growth of Short-Chain Fatty Acid Producers.

Park H, Yu D, Hong S, Lee J, Park S, Park M Immune Netw. 2025; 24(6):e41.

PMID: 39801739 PMC: 11711128. DOI: 10.4110/in.2024.24.e41.

CXCL13: a common target for immune-mediated inflammatory diseases.

Hui L, Li Y, Huang M, Jiang Y, Liu T Clin Exp Med. 2024; 24(1):244.

PMID: 39443356 PMC: 11499446. DOI: 10.1007/s10238-024-01508-8.

Methylation of T and B Lymphocytes in Autoimmune Rheumatic Diseases.

Deng T, Wang Z, Geng Q, Wang Z, Jiao Y, Diao W Clin Rev Allergy Immunol. 2024; 66(3):401-422.

PMID: 39207646 DOI: 10.1007/s12016-024-09003-4.

Immune profiling analysis of double-negative T cells in patients with systemic sclerosis.

Zhang D, Alip M, Chen H, Wu D, Zhu H, Han Y Clin Rheumatol. 2024; 43(5):1623-1634.

PMID: 38436769 DOI: 10.1007/s10067-024-06920-9.

Immune Profiling of Patients with Systemic Sclerosis through Targeted Proteomic Analysis.

Szabo I, Badii M, Gaal I, Szabo R, Sirbe C, Humita O Int J Mol Sci. 2023; 24(24).

PMID: 38139427 PMC: 10744051. DOI: 10.3390/ijms242417601.

References

Rabquer B, Tsou P, Hou Y, Thirunavukkarasu E, Haines 3rd G, Impens A . Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther. 2011; 13(1):R18. PMC: 3241362. DOI: 10.1186/ar3242. View

Farina G, York M, Di Marzio M, Collins C, Meller S, Homey B . Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol. 2010; 130(11):2583-93. PMC: 3086558. DOI: 10.1038/jid.2010.200. View

Kraling B, Maul G, Jimenez S . Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology. 1995; 63(1):48-56. DOI: 10.1159/000163933. View

Groom J, Luster A . CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011; 89(2):207-15. PMC: 3863330. DOI: 10.1038/icb.2010.158. View

Gruschwitz M, Hornstein O, von den Driesch P . Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum. 1995; 38(2):184-9. DOI: 10.1002/art.1780380206. View

. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5):581-90. DOI: 10.1002/art.1780230510. View

Roumm A, Whiteside T, Medsger Jr T, Rodnan G . Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984; 27(6):645-53. DOI: 10.1002/art.1780270607. View

Michalska-Jakubus M, Kowal-Bielecka O, Chodorowska G, Bielecki M, Krasowska D . Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology (Oxford). 2010; 50(4):746-55. DOI: 10.1093/rheumatology/keq392. View

Gouwy M, Schiraldi M, Struyf S, Van Damme J, Uguccioni M . Possible mechanisms involved in chemokine synergy fine tuning the inflammatory response. Immunol Lett. 2012; 145(1-2):10-4. DOI: 10.1016/j.imlet.2012.04.005. View

10.

Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos J . Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum. 2001; 44(6):1382-6. DOI: 10.1002/1529-0131(200106)44:6<1382::AID-ART231>3.0.CO;2-T. View

11.

Sakkas L, Xu B, Artlett C, Lu S, Jimenez S, Platsoucas C . Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol. 2002; 168(7):3649-59. DOI: 10.4049/jimmunol.168.7.3649. View

12.

Westermann J, Nguyen-Hoai T, Baldenhofer G, Hopken U, Lipp M, Dorken B . CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther. 2007; 14(6):523-32. DOI: 10.1038/sj.cgt.7701042. View

13.

Carulli M, Ong V, Ponticos M, Shiwen X, Abraham D, Black C . Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum. 2005; 52(12):3772-82. DOI: 10.1002/art.21396. View

14.

Artlett C . Immunology of systemic sclerosis. Front Biosci. 2005; 10:1707-19. DOI: 10.2741/1654. View

15.

Yamashita M, Iwama N, Date F, Shibata N, Miki H, Yamauchi K . Macrophages participate in lymphangiogenesis in idiopathic diffuse alveolar damage through CCL19-CCR7 signal. Hum Pathol. 2009; 40(11):1553-63. DOI: 10.1016/j.humpath.2009.03.021. View

16.

Farina G, Lafyatis D, Lemaire R, Lafyatis R . A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2010; 62(2):580-8. PMC: 3018285. DOI: 10.1002/art.27220. View

17.

Ludwig R, Hardt K, Hatting M, Bistrian R, Diehl S, Radeke H . Junctional adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin. Immunology. 2009; 128(2):196-205. PMC: 2767309. DOI: 10.1111/j.1365-2567.2009.03100.x. View

18.

Jun J, Kuechle M, Harlan J, Elkon K . Fibroblast and endothelial apoptosis in systemic sclerosis. Curr Opin Rheumatol. 2003; 15(6):756-60. DOI: 10.1097/00002281-200311000-00012. View

19.

Ohl L, Mohaupt M, Czeloth N, Hintzen G, Kiafard Z, Zwirner J . CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity. 2004; 21(2):279-88. DOI: 10.1016/j.immuni.2004.06.014. View

20.

Sakkas L, Platsoucas C . Is systemic sclerosis an antigen-driven T cell disease?. Arthritis Rheum. 2004; 50(6):1721-33. DOI: 10.1002/art.20315. View